Merck & Co. Inc. completes a $10 billion acquisition of Verona Pharma, making it a wholly-owned subsidiary. The acquisition adds Ohtuvayre, a COPD drug, to Merck’s cardio-pulmonary portfolio as the first novel inhaled mechanism for COPD maintenance treatment in over 20 years. Ohtuvayre is also being evaluated for non-cystic fibrosis bronchiectasis. Merck offers human health pharmaceuticals, veterinary pharmaceuticals, vaccines, and health management solutions worldwide. While Merck is seen as a solid investment, there are AI stocks with greater potential and less risk. For more information on undervalued AI stocks, check out the free report on the best short-term AI stock.

Read more at Yahoo Finance: Merck Completes $10B Acquisition of Verona Pharma, Adds COPD Drug Ohtuvayre